home All News open_in_new Full Article
Nymox Announces Dismissal of Delaware Action Against Ascella
Nymox announced the dismissal of its Delaware action against Ascella on March 7, 2025. CEO Paul Averback stated the dismissal was a legal step after consulting with counsel. Nymox is seeking approval to market its drug NYMOZARFEX for BPH. The company also reported 10-year follow-up data from U.S. patients.
today 2 d. ago attach_file Other
attach_file
Other
attach_file
Other
attach_file
Other
attach_file
Other
attach_file
Culture
attach_file
Technology
attach_file
Sport
attach_file
Economics
attach_file
Transport
attach_file
Other
attach_file
Economics
attach_file
Culture
attach_file
Other
attach_file
Other
attach_file
Economics
ID: 2855290491